Femasys Inc.

Femasys Inc. is a biomedical company founded in February 2004, headquartered in Suwanee, Georgia, dedicated to transforming women's healthcare. The company's mission is to provide women worldwide with superior minimally-invasive, non-surgical product technologies that are accessible in the office, thereby improving patient care and overall health economics. Femasys is led by its founder, President, and CEO, Kathy Lee-Sepsick.

Femasys develops a broad portfolio of in-office therapeutic and diagnostic products primarily focused on reproductive health. Key product candidates and commercialized solutions include FemaSeed, an intratubal insemination solution for infertility; FemBloc, a non-surgical permanent birth control method; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemCerv, an endocervical sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for fallopian tube evaluation; FemChec, a controlled contrast-generating device for fallopian tube diagnosis; and FemSperm, a sperm preparation and analysis product line. These technologies aim to address significant unmet needs in areas such as infertility, contraception, and cancer diagnostics.

In recent news, Femasys launched FemaSeed® Complete for OB/GYNs on April 22, 2026, and expanded its international presence with an Israeli market entry for its fertility portfolio on April 16, 2026. The company also appointed John Canning as Chief Operating Officer on April 1, 2026. Femasys is actively advancing FemBloc toward U.S. approval, having initiated pivotal trial enrollment on March 10, 2026, following its regulatory approval in Europe (June 2025), the UK (August 2025), and New Zealand (September 2025). Additionally, FemBloc achieved MDSAP Certification on February 26, 2026, and FemaSeed received AMA CPT Editorial Panel approval for a new Category III CPT code on February 23, 2026.